American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 | Latest News RSS Feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 - Latest News


American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and

Before it's here, it's on the Bloomberg Terminal. read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology ... per the AACE/ACE guidelines, SGLT2 inhibitors are preferred to alternative antidiabetic ... read more

Insider Tips on Routine Diabetes Lab Tests

There are several routine medical tests that people with diabetes are supposed to get regularly, and while they are important, the results are not always as simple as we’ve been led to believe. Even ... read more

Looking for another news?


Promise of T1D Vaccines; Can Bariatric Surgery Be Essential?

of King's College London. (The Lancet Diabetes & Endocrinology) Compared with DPP-4 inhibitors, SGLT-2 inhibitors -- dapagliflozin (Farxiga), empagliflozin (Jardiance), and canagliflozin (Invokana ... read more


Best Treatments for Type 2 Diabetes

Type 2 diabetes is one of the most serious ... Medical experts don't all agree exactly how often adults should have a diabetes test. The American Diabetes Association advises that everyone aged ... read more

Sulfonylurea Use and the Risk of Hospital Readmission in Patients With Type 2 Diabetes

This study documented, using a nationally representative database from 1999 to 2010, 2.6 million patients with type 2 diabetes and with multiple hospitalizations. Patients treated with SU ... read more

Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ... read more

AstraZeneca’s CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus

Before it's here, it's on the Bloomberg Terminal. read more

Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®

Before it's here, it's on the Bloomberg Terminal. read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us